These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27838913)

  • 21. Effectiveness and cost-effectiveness of knowledge transfer and behavior modification interventions in type 2 diabetes mellitus patients--the INDICA study: a cluster randomized controlled trial.
    Ramallo-Fariña Y; García-Pérez L; Castilla-Rodríguez I; Perestelo-Pérez L; Wägner AM; de Pablos-Velasco P; Domínguez AC; Cortés MB; Vallejo-Torres L; Ramírez ME; Martín PP; García-Puente I; Salinero-Fort MÁ; Serrano-Aguilar PG;
    Implement Sci; 2015 Apr; 10():47. PubMed ID: 25880498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective Treatment Recommendations for Type 2 Diabetes Management Using Reinforcement Learning: Treatment Recommendation Model Development and Validation.
    Sun X; Bee YM; Lam SW; Liu Z; Zhao W; Chia SY; Abdul Kadir H; Wu JT; Ang BY; Liu N; Lei Z; Xu Z; Zhao T; Hu G; Xie G
    J Med Internet Res; 2021 Jul; 23(7):e27858. PubMed ID: 34292166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM.
    Willis M; Fridhammar A; Gundgaard J; Nilsson A; Johansen P
    Pharmacoeconomics; 2020 Sep; 38(9):953-969. PubMed ID: 32399797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and Validation of PREDICT-DM: A New Microsimulation Model to Project and Evaluate Complications and Treatments of Type 2 Diabetes Mellitus.
    Kazemian P; Wexler DJ; Fields NF; Parker RA; Zheng A; Walensky RP
    Diabetes Technol Ther; 2019 Jun; 21(6):344-355. PubMed ID: 31157568
    [No Abstract]   [Full Text] [Related]  

  • 25. Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment.
    Jahn B; Rochau U; Kurzthaler C; Paulden M; Kluibenschädl M; Arvandi M; Kühne F; Goehler A; Krahn MD; Siebert U
    Med Decis Making; 2016 Apr; 36(3):375-90. PubMed ID: 26476865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reporting Quality of Discrete Event Simulations in Healthcare-Results From a Generic Reporting Checklist.
    Zhang X; Lhachimi SK; Rogowski WH
    Value Health; 2020 Apr; 23(4):506-514. PubMed ID: 32327168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data.
    Corro Ramos I; van Voorn GAK; Vemer P; Feenstra TL; Al MJ
    Value Health; 2017 Sep; 20(8):1041-1047. PubMed ID: 28964435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus.
    Pollock RF; Norrbacka K; Boye KS; Osumili B; Valentine WJ
    J Med Econ; 2022; 25(1):393-402. PubMed ID: 35105267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictions Burden of Diabetes and Economics Cost: Contributing Risk Factors of Changing Disease Prevalence and its Pandemic Impact to Qatar.
    Bener A; Al-Hamaq AO
    Exp Clin Endocrinol Diabetes; 2016 Sep; 124(8):504-511. PubMed ID: 27023007
    [No Abstract]   [Full Text] [Related]  

  • 30. External validation of type 2 diabetes computer simulation models: definitions, approaches, implications and room for improvement-a protocol for a systematic review.
    Ogurtsova K; Heise TL; Linnenkamp U; Dintsios CM; Lhachimi SK; Icks A
    Syst Rev; 2017 Dec; 6(1):267. PubMed ID: 29284543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decision models in type 2 diabetes mellitus: A systematic review.
    Li J; Bao Y; Chen X; Tian L
    Acta Diabetol; 2021 Nov; 58(11):1451-1469. PubMed ID: 34081206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
    Wang B; Roth JA; Nguyen H; Felber E; Furnback W; Garrison LP
    PLoS One; 2015; 10(4):e0121915. PubMed ID: 25849542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of a diabetes collaborative care management program on clinical and economic outcomes in patients with type 2 diabetes.
    McAdam-Marx C; Dahal A; Jennings B; Singhal M; Gunning K
    J Manag Care Spec Pharm; 2015 Jun; 21(6):452-68. PubMed ID: 26011547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7.
    Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
    Med Decis Making; 2012; 32(5):733-43. PubMed ID: 22990088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic literature review of the health economic implications of early detection by screening populations at risk for type 2 diabetes.
    Einarson TR; Bereza BG; Acs A; Jensen R
    Curr Med Res Opin; 2017 Feb; 33(2):331-358. PubMed ID: 27819150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
    Fonseca T; Clegg J; Caputo G; Norrbacka K; Dilla T; Alvarez M
    J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model.
    McEwan P; Ward T; Bennett H; Bergenheim K
    Cost Eff Resour Alloc; 2015; 13():12. PubMed ID: 26244041
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.